招商通知 第三届全球手术机器人大会 第二届全球医疗科技大会 近日，西门子医疗发布了 首款 国产高端诊断设备—— Atellica全自动生化免疫分析仪 。同时， 复星诊断与西门子医疗正式宣布达成战略合作 ，推出 首个联合新 品 —— 国产生化试剂解决方案 。这一合作标志着中国本土医疗科技企业与国际巨头在深化本土创新、提升高端国产诊断产品可及性方面迈入了新阶段。 # Atellica全自动生化免疫分析仪正式投产 西门子医疗在上海研发与生产基地正式投产了其 首款国产高端实验室诊断设备——Atellica全自动生化免疫分析仪 。这标志着西门子医疗在亚太地区的首个实验室 诊断仪器产线正式启用。 产品特点： 全球品质标准 ：Atellica全自动生化免疫分析仪全面传承了西门子医疗全球品质标准，通过 自动质控、视觉识别、磁动轨道以及温湿度控制等 前沿技术，实 现了质量与效率的双重提升。 高效检测性能 ：该设备 占地面积仅6㎡ ，能够满足急诊实验室对空间的严格要求。凭借其 高速高效的检测性能 ，可助力急诊临床在紧急情况下迅速做出诊 断，为守护患者生命健康争取宝贵时间。 优化工作流程 ：以 北京协和医院 为例，使用该设备后，在 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 回購股份的進展公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* 董事長 陳玉卿 中國，上海 2025 年7 月2 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、潘東輝先生及吳以芳先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生及楊玉成先生；以及本公司之職工董事為嚴佳女士。 * 僅供識別 证券 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 FF301 截至月份: 2025年6月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海復星醫藥(集團)股份有限公司 ( 於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年7月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02196 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 551,940,500 | RMB | | 1 RMB | | 551,940,500 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 551,940,500 | RMB | | 1 RMB | | 551,940,500 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 控股子公司獲歐盟藥品GMP證書的公告》，僅供參閱。 承董事會命 陳玉卿 中國，上海 2025 年7 月2 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、潘東輝先生及吳以芳先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生及楊玉成先生；以及本公司之職工董事為嚴佳女士。 * 僅供識別 证券代码：600196 股票 ...

上海复星医药（集团）股份有限公司 关于回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示（简称同正文） 截至 2025 年 6 月 30 日收市，回购进展如下： | | A 股回购方案 | H 股回购方案 | | --- | --- | --- | | 回购方案 | 2025/1/23 | 2025/1/23 | | 首次披露日 | | | | 回购方案 | 2025/1/22~2025/7/21 | 2025/1/22~2025/7/21 | | 实施期限 | | | | （含首尾两日） | | | | 预计回购金额 | 人民币30,000万元~60,000万元 | 不适用 | | | □减少注册资本 | 包括但不限于注销或作为库存 | | | √用于员工持股计划或股权激励 | 股份等 | | 回购用途 | √用于转换公司可转债 | | | | □为维护公司价值及股东权益 | | | | （上述二者之一或二者皆有） | | | 累计已回购股数 | 14,228,552股A 股 | 3,410,5 ...

一、GMP证书相关情况 证券代码：600196 股票简称：复星医药 编号：临 2025-111 上海复星医药（集团）股份有限公司 关于控股子公司获欧盟药品 GMP 证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，上海复星医药（集团）股份有限公司（以下简称"本公司"）控股子 公司上海复宏汉霖生物医药有限公司收到比利时联邦药品和保健产品管理局 （Federal Agency For Medicines And Health Products）就HLX11（重组抗HER2 结构域Ⅱ人源化单克隆抗体注射液，即帕妥珠单抗注射液）、HLX14（重组抗RANKL 全人单克隆抗体注射液，即地舒单抗生物注射液）所涉生产设施颁发的 《Certificate of GMP Compliance of a Manufacturer》（即《药品GMP证书》） （以下简称"本次GMP认证"），现就相关情况公告如下： 企业名称：上海复宏汉霖生物医药有限公司 地址：上海市松江区文俊路182号1幢、上海市松江区文俊路618弄 证书编号：BE/ ...

Core Viewpoint - Fosun Pharma's subsidiary has received EU GMP certification for two injectable drugs, which may enhance its market position but has uncertain sales impacts [1] Group 1: Company Announcement - Fosun Pharma announced that its subsidiary, Shanghai Fuhong Hanlin Biopharmaceutical Co., Ltd., received the GMP certificate from the Belgian Federal Agency for Medicines and Health Products [1] - The certified products are Pertuzumab injection (HLX11) and Dexamethasone injection (HLX14) [1] Group 2: Financial Implications - The total investment in the production facilities related to this GMP certification is approximately RMB 235.82 million [1] - The projected global sales for Pertuzumab injection in 2024 are about USD 3.322 billion, while for Dexamethasone injection, it is approximately USD 7.462 billion [1] - The GMP certification is not expected to have a significant impact on the company's current performance, and the sales of the drugs may be influenced by various uncertain factors [1]

Financial Performance Highlights - Revenue reached RMB 41,067 million, a year-on-year decrease of 080%[5] - R&D expense was RMB 3,644 million, a year-on-year decrease of 1615%[6] - Net profit attributable to shareholders was RMB 2,770 million, a year-on-year increase of 1608%[7] - Net operating cash flow reached RMB 4,470 million, a year-on-year increase of 3113%[6] Key Products and R&D - Serplulimab Injection (PD-1) achieved revenue of RMB 1,313 million in 2024[68, 130] - Pharma R&D expenditure was RMB 4,910 million, accounting for 1698% of Pharma revenue[63, 67] - Axicabtagene Ciloleucel Injection has benefited over 800 patients since approval in 2021[43, 75, 132] Global Operations and Internationalization - Revenue from countries and regions outside Chinese mainland reached RMB 11,297 million, a year-on-year increase of 893%[30] - Sisram's direct sales revenue increased to 87%[36, 100] Medical Devices - Sisram Medical's revenue was USD 3590 million in 2024[99] - 58 Da Vinci Surgical Systems were installed in China in 2024[108] Sinopharm Performance - Pharmaceutical distribution segment revenue recorded RMB 444,365 million, a year-on-year increase of 075%[121] - Medical device distribution segment revenue recorded RMB 117,915 million, a year-on-year decrease of 944%[121] - Retail pharmacy segment revenue recorded RMB 35,981 million, a year-on-year increase of 082%[121]

Financial Performance - Revenue reached RMB 9,420 million, a decrease of 726% year-over-year[6] - R&D expense was RMB 737 million, down 1110% year-over-year[7] - Net profit attributable to shareholders was RMB 765 million, an increase of 2542% year-over-year[8] - Net operating cash flow increased to RMB 1,056 million, up 1508% year-over-year[7] - 2024 Pharma R&D expenditure was RMB 4,910 million, accounting for 1698% of Pharma revenue[61] Key Products & Pipelines Progress - Serplulimab Injection (PD-1) received EMA approval for ES-SCLC treatment[12] - Tenapanor Hydrochloride Tablets approved by NMPA for serum phosphorus control in adult dialysis patients with chronic kidney disease[13] - Fosun Pharma achieved a revenue of RMB 11,297 million (+893% YoY) from countries and regions outside Chinese mainland in 2024[26] Med Tech Segment - Med Tech segment revenue reached RMB 4,390 million[87] - Sisram Medical's revenue was USD 3590 million in 2024[96] Healthcare Services - Healthcare Services segment revenue was RMB 6,672 million[108] Sinopharm Performance - Pharmaceutical distribution segment revenue recorded RMB 444,365 million (+075% YoY)[116] - Medical device distribution segment revenue recorded RMB 117,915 million (-944% YoY)[116] - Revenue of the retail pharmacy segment recorded RMB 35,981 million (+082% YoY)[116]

Core Viewpoint - Fosun Pharma's subsidiary, Fuhong Hanlin, has signed a licensing agreement with FBD to collaborate on the development, production, and commercialization of the investigational drug HCB101, a SIRPα-Fc fusion protein for cancer treatment [1][2]. Group 1: Licensing Agreement Details - Fuhong Hanlin will pay up to $59 million to FBD and up to $143 million in milestone payments based on annual net sales of the licensed product in specific regions [1]. - The agreement includes royalty payments based on a one to two-digit percentage of annual net sales of the licensed product, with potential reductions under certain conditions [1]. - The agreement allows Fuhong Hanlin to terminate the contract if FBD reaches major financial terms with third parties regarding the licensed product [1]. Group 2: Product Information - HCB101 is a SIRPα-Fc fusion protein that enhances macrophage phagocytosis of tumor cells by binding with high affinity to CD47 [2]. - The HCB101 injection has shown preliminary efficacy in early clinical trials for tumor patients, including those with solid tumors, and is currently in the Ib/IIa clinical trial phase in China [2]. Group 3: Company Background - FBD, established in 2021 and based in Hong Kong, is a subsidiary of Hanchor Bio Inc., which focuses on new drug development in the field of cancer immunotherapy [3]. - As of December 31, 2024, Hanchor Bio Inc. reported total assets of approximately NT$5.42 billion, equity of about NT$2.31 billion, and total liabilities of around NT$3.11 billion, with a net loss of approximately NT$1.354 billion and no operating revenue for 2024 [3]. - The collaboration aims to leverage both companies' strengths in drug development and commercialization to enhance Fosun Pharma's product pipeline in oncology and provide more treatment options for patients [3].